Show simple item record

dc.contributor.authorD'Erme, A.M.*
dc.contributor.authorWilsmann-Theis, D.*
dc.contributor.authorWagenpfeil, J.*
dc.contributor.authorHolzel, M.*
dc.contributor.authorFerring-Schmitt, S.*
dc.contributor.authorSternberg, S.*
dc.contributor.authorWittmann, Miriam*
dc.contributor.authorPeters, B.*
dc.contributor.authorBosio, A.*
dc.contributor.authorBieber, T.*
dc.contributor.authorWenzel, J.*
dc.date.accessioned2016-09-21T13:14:25Z
dc.date.available2016-09-21T13:14:25Z
dc.date.issued2015-04
dc.identifier.citationD'Erme AM, Wilsmann-Theis D, Wagenpfeil J et al (2015) IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. Journal of Investigative Dermatology. 135(4): 1025-1032.
dc.identifier.urihttp://hdl.handle.net/10454/9050
dc.descriptionNo
dc.description.abstractIn recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not only psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/tumor necrosis factor-alpha (TNFalpha)-associated genes specifically expressed in psoriasis, among which IL-36gamma was the most outstanding marker. In subsequent immunohistological analyses, IL-36gamma was confirmed to be expressed in psoriasis lesions only. IL-36gamma peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFalpha-treatment. Furthermore, IL-36gamma immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36gamma as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36gamma might also provide a future drug target, because of its potential amplifier role in TNFalpha- and IL-17 pathways in psoriatic skin inflammation.
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG) to JW (WE-4428), the René Touraine Foundation (for AD), and the PTJ reference number 0306v12 as part of the Technology and Innovation Program (TIP) North-Rhine Westphalia (gene expression analyses)
dc.relation.isreferencedbyhttp://dx.doi.org/10.1038/jid.2014.532
dc.subjectBiomarkers
dc.subject; Biopsy
dc.subject; Gene expression profiling
dc.subject; Gene expression regulation
dc.subject; Humans
dc.subject; Immunohistochemistry
dc.subject; Inflammation
dc.subject; Interleukin-1
dc.subject; Interleukin-17
dc.subject; Predictive value of tests
dc.subject; Psoriasis
dc.subject; Skin diseases
dc.titleIL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions
dc.status.refereedYes
dc.date.Accepted2014-12-08
dc.date.application2015-01-22
dc.typeArticle
dc.type.versionNo full-text in the repository


This item appears in the following Collection(s)

Show simple item record